ClinicalTrials.gg
RecruitingNCT07106762Updated Jul 29, 2026

Phase 2/3 Trial of Izalontamab Brengitecan vs Platinum-based Chemotherapy for Metastatic Urothelial Cancer With Disease Progression on or After Immunotherapy

A Phase 2/3 interventional study of Iza-bren and Cisplatin in Urothelial Cancer, sponsored by Bristol-Myers Squibb. Recruiting at 163 sites in 22 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-29.

Sponsored by Bristol-Myers Squibb · Phase 2/3, Interventional, and Treatment

From the registry’s dates

  • Started Sep 2025; still recruiting 1 year 1 month later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
470
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 11 studies in Urinary Bladder Neoplasms by Bristol-Myers Squibb — 1 open to participants now, 1 under way, 1 of them phase 3. Urinary Bladder Neoplasms · Bristol-Myers Squibb.

Planned enrollment
2nd of 10
470 · median 128
Started
2025
the only one that year
Phase 2/3
2 of 11
1 open now
Registered
11th of 11
by date

Among the 11 studies in Urinary Bladder Neoplasms by Bristol-Myers Squibb, this one is the 2nd largest by planned enrollment of the 10 interventional ones that give a count, is the only one that started in 2025, is one of 2 in phase 2/3, and was the 11th registered.

Urinary Bladder Neoplasms

1,800 studies on the registry are indexed under Urinary Bladder Neoplasms; 446 are open to participants now.

Browse Urinary Bladder Neoplasms studies →

Open to participants now

1 of the 11 studies in Urinary Bladder Neoplasms by Bristol-Myers Squibb is open now, in 12 countries.

By country, each count listing its studies:

Who these studies take

Of the 336 Urinary Bladder Neoplasms studies recruiting now, 256 (76%) set no upper age limit and 22 (7%) stop at 75 or younger; 22 take children under 18; 21 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 11 studies in Urinary Bladder Neoplasms by Bristol-Myers Squibb, or all of them as a file.
02

Study summary

A Phase 2/3 Trial of Izalontamab Brengitecan vs Platinum-based Chemotherapy for Metastatic Urothelial Cancer with Disease Progression on or After Immunotherapy

03

Conditions studied

  • Urothelial Cancer

Keywords

  • Bladder cancer
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants must have confirmed advanced urothelial carcinoma.
  • Participants must be eligible to receive platinum-based chemotherapy.
  • Participants must be Anti-PD-(L)1-experienced (in locally advanced or setting), either in combination with or sequential to another systemic therapy.
  • Participants treated only in the peri-operative setting must have within 12 months of the last dose of the treatment.
  • Participants must have ≥ 1 per v1.1.
  • Participants must have (ECOG) Performance Status 0-1.

Exclusion criteria

Exclusion Criteria:

  • Participants must not have platinum-based chemotherapy exposure within 12 months.
  • Participants must not have received >2 prior regimens irrespective of the setting.
  • Participants must not have prior ADC therapy targeting EGFR or HER3.
  • Participants must not have prior therapy with topoisomerase 1 inhibitor.
  • Participants must not have active, untreated .
  • Other protocol-defined inclusion/exclusion criteria apply.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
470 participants (estimated)

Study arms

  • Experimental
    Arm A

    Drug: Iza-bren

  • Experimental
    Arm B

    Drug: Iza-bren

  • Active comparator
    Arm C

    Drug: Cisplatin · Drug: Gemcitabine · Drug: Carboplatin

  • Experimental
    Arm D

    Drug: Iza-bren

  • Active comparator
    Arm E

    Drug: Cisplatin · Drug: Gemcitabine · Drug: Carboplatin

Interventions

  • Specified dose on specified days

    Also known as: BMS-986507, BL-B01D1, Izalontamab brengitecan

  • Specified dose on specified days

  • Specified dose on specified days

  • Specified dose on specified days

06

What researchers measure

Primary outcomes

  1. Phase 2: Recommended Phase 3 Dose (RP3D) of BMS-986507

    Time frame: Approximately 3 months

  2. Phase 3: Progression-Free Survival (PFS)

    Assessed using Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1) per blinded independent central review (BICR)

    Time frame: Up to 5 years

  3. Phase 3: Overall Survival (OS)

    Time frame: Up to 5 years

Secondary outcomes

  1. Phase 2: Objective Response (OR)

    Assessed using Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1) by investigator

    Time frame: Up to 5 years

  2. Phase 2: PFS

    Assessed using RECIST v1.1 by investigator

    Time frame: Up to 5 years

  3. Phase 2: Duration of Response (DOR)

    Assessed using RECIST v1.1 by investigator

    Time frame: Up to 5 years

  4. Phase 2: Time to Response (TTR)

    Assessed using RECIST v1.1 by investigator

    Time frame: Up to 5 years

  5. Phase 2: OS

    Time frame: Up to 5 years

  6. Phase 2: Iza-bren antibody-drug conjugate (ADC) concentration

    Time frame: Up to 5 years

  7. Phase 2: Iza-bren total antibody concentration

    Time frame: Up to 5 years

  8. Phase 2: Iza-bren Ed-04 payload concentration

    Time frame: Up to 5 years

  9. Phase 2: Iza-bren observed concentration at end of infusion (Ceoi)

    Time frame: Up to 5 years

  10. Phase 2: Iza-bren trough observed concentration (Ctrough)

    Time frame: Up to 5 years

  11. Phase 3: OR

    As per RECIST v1.1 by BICR

    Time frame: Up to 5 years

  12. Phase 3: DoR

    As per RECIST v1.1 by BICR

    Time frame: Up to 5 years

  13. Phase 3: TTR

    As per RECIST v1.1 by BICR

    Time frame: Up to 5 years

  14. Phase 3: Time until definitive deterioration in the EORTC QLQ-C30 Global Health Status/Quality of Life (GHS/QoL) scale

    Time frame: Up to 5 years

07

Study locations

122 of 163 sites recruiting
  • Local Institution - 0167
    Gilbert, Arizona 85234, United States
    Not yet recruiting
    • Site 0167 · Contact
  • Local Institution - 0162
    Fullerton, California 92835, United States
    Not yet recruiting
    • Site 0162 · Contact
  • Palo Alto Center-Palo Alto Medical Foundation Research Institute
    Palo Alto, California 94304, United States
    Recruiting
    • Nitin Rohatgi, Site 0252 · Contact000-000-0000
  • Sutter Health - Sutter Institute for Medical Research
    Sacramento, California 95816, United States
    Recruiting
    • Nitin Rohatgi, Site 0163 · Contact000-000-0000
  • University of California Davis (UC Davis) Comprehensive Cancer Center
    Sacramento, California 95817, United States
    Recruiting
    • Mamta Parikh, Site 0139 · Contact916-734-3772
  • Pacific Hematology Oncology Associates
    San Francisco, California 94115, United States
    Recruiting
    • Nitin Rohatgi, Site 0251 · Contact000-000-0000
  • Sutter Santa Rosa
    Santa Rosa, California 95403, United States
    Recruiting
    • Nitin Rohatgi, Site 0254 · Contact000-000-0000
  • Rocky Mountain Cancer Centers, LLP
    Denver, Colorado 80218, United States
    Recruiting
    • Manojkumar Bupathi, Site 0185 · Contact303-418-7639
  • Local Institution - 0245
    Dillon, Colorado 80435, United States
    Withdrawn

    Not enrolling at this site — choose another above.

  • Shaw Cancer Center
    Edwards, Colorado 81632, United States
    Recruiting
    • Erin Schwab, Site 0191 · Contact970-569-7608
  • Sibley Memorial Hospital
    Washington D.C., District of Columbia 20016, United States
    Recruiting
    • Jean Hoffman-Censits, Site 0250 · Contact267-760-5194
  • Miami Cancer Institute at Baptist Health, Inc.
    Miami, Florida 33176, United States
    Recruiting
    • Rohan Garje, Site 0247 · Contact786-596-2000
  • University of Kentucky Chandler Medical Center
    Lexington, Kentucky 40536, United States
    Recruiting
    • Zin Myint, Site 0193 · Contact859-323-2964
  • Johns Hopkins Hospital
    Baltimore, Maryland 21287, United States
    Recruiting
    • Jean Hoffman-Censits, Site 0232 · Contact267-760-5194
  • Local Institution - 0195
    Boston, Massachusetts 02215, United States
    Not yet recruiting
    • Site 0195 · Contact
  • Karmanos Cancer Institute
    Detroit, Michigan 48201, United States
    Recruiting
    • Yusra Shao, Site 0168 · Contact000-000-0000
  • Local Institution - 0248
    Buffalo, New York 14203, United States
    Withdrawn

    Not enrolling at this site — choose another above.

  • Icahn School of Medicine at Mount Sinai
    New York, New York 10029, United States
    Recruiting
    • Matthew Galsky, Site 0086 · Contact212-824-8583
  • Memorial Sloan Kettering Cancer Center
    New York, New York 10065, United States
    Recruiting
    • Jonathan Rosenberg, Site 0088 · Contact646-422-4461
  • Fairview Hospital
    Cleveland, Ohio 44111, United States
    Recruiting
    • Shilpa Gupta, Site 0256 · Contact216-296-5457
  • Cleveland Clinic
    Cleveland, Ohio 44195, United States
    Recruiting
    • Shilpa Gupta, Site 0192 · Contact216-296-5457
  • The James Outpatient Care West Campus
    Columbus, Ohio 43221, United States
    Recruiting
    • Lingbin Meng, Site 0161 · Contact502-424-8792
  • Cleveland Clinic - Hillcrest Hospital
    Mayfield Heights, Ohio 44124, United States
    Recruiting
    • Shilpa Gupta, Site 0257 · Contact216-296-5457
  • Local Institution - 0141
    Portland, Oregon 97239, United States
    Not yet recruiting
    • Site 0141 · Contact
  • SCRI Oncology Partners
    Nashville, Tennessee 37203, United States
    Recruiting
    • Benjamin Garmezy, Site 0186 · Contact713-444-7804
  • Local Institution - 0084
    Nashville, Tennessee 37232, United States
    Not yet recruiting
    • Site 0084 · Contact
  • Texas Oncology - West Texas
    Abilene, Texas 79606, United States
    Recruiting
    • Srikar Malireddy, Site 0249 · Contact940-691-8271
  • Local Institution - 0187
    Austin, Texas 78705, United States
    Not yet recruiting
    • Site 0187 · Contact
  • Intermountain Medical Center
    Murray, Utah 84107, United States
    Recruiting
    • David Gill, Site 0111 · Contact913-568-7449
  • St George Regional Hospital Cancer Center
    St. George, Utah 84790, United States
    Recruiting
    • David Gill, Site 0253 · Contact913-568-7449
  • University of Virginia Health System
    Charlottesville, Virginia 22903, United States
    Recruiting
    • Paul Viscuse, Site 0158 · Contact434-924-9333
  • Local Institution - 0188
    Norfolk, Virginia 23502, United States
    Not yet recruiting
    • Site 0188 · Contact
  • Local Institution - 0200
    Seattle, Washington 98101, United States
    Not yet recruiting
    • Site 0200 · Contact
  • Fred Hutchinson Cancer Center
    Seattle, Washington 98109, United States
    Recruiting
    • Rosa Nadal, Site 0255 · Contact206-606-1406
  • University of Washington Medical Center - Montlake
    Seattle, Washington 98195, United States
    Recruiting
    • Rosa Nadal Rios, Site 0259 · Contact000-000-0000
  • Instituto Alexander Fleming
    Caba, Buenos Aires 1426, Argentina
    Recruiting
    • Juan Pablo Sade, Site 0023 · Contact5432218900
  • Hospital Británico de Buenos Aires
    CABA, Buenos Aires CP1280AEB, Argentina
    Recruiting
    • Ernesto Korbenfeld, Site 0028 · Contact54911563819972
  • Asociación de Beneficencia Hospital Sirio Libanés
    Ciudad Autonoma de Buenos Aires, Buenos Aires 1419, Argentina
    Recruiting
    • Hernan Cutuli, Site 0026 · Contact5491157654803
  • Hospital Italiano de Buenos Aires
    ABB, Buenos Aires F.D. C1199ABB, Argentina
    Recruiting
    • Federico Cayol, Site 0024 · Contact054911555933332
  • IONC Instituto Oncologico de Cordoba - Fundacion Richardet Longo
    Córdoba, 5000, Argentina
    Recruiting
    • Martin Richardet, Site 0025 · Contact5493516165267
  • Fundacion Centro Oncologico de Integración Regional
    Mendoza, M5500AYB, Argentina
    Recruiting
    • Mauricio Fernandez, Site 0027 · Contact9542614666010
  • Macquarie University
    Macquarie University, New South Wales 2109, Australia
    Recruiting
    • Alison Zhang, Site 0149 · Contact+61298122956
  • GenesisCare North Shore
    St Leonards, New South Wales 2065, Australia
    Recruiting
    • Laurence Krieger, Site 0151 · Contact61294631172
  • Austin Health
    Heidelberg, Victoria 3084, Australia
    Recruiting
    • Andrew Weickhardt, Site 0150 · Contact+61394965000
  • Medizinische Universität Wien
    Vienna, State of Vienna 1090, Austria
    Recruiting
    • Kilian Gust, Site 0109 · Contact004367761942300
  • Klinik Ottakring
    Vienna, State of Vienna 1160, Austria
    Recruiting
    • Dora Niedersuess-Beke, Site 0131 · Contact+431491502145
  • Medizinische Universitaet Innsbruck
    Innsbruck, Tyrol 6020, Austria
    Recruiting
    • Renate Pichler, Site 0155 · Contact4351250424811
  • ZAS Augustinus
    Wilrijk, Antwerpen 2610, Belgium
    Recruiting
    • Tom Van den Mooter, Site 0013 · Contact+3234433011
  • AZ Maria Middelares
    Ghent, Oost-Vlaanderen 9000, Belgium
    Recruiting
    • Christof Vulsteke, Site 0014 · Contact+3292464646
  • UZ Gent
    Ghent, Oost-Vlaanderen 9000, Belgium
    Recruiting
    • Sylvie Rottey, Site 0011 · Contact+3293322111
  • Centre Hospitalier Universitaire de Liège - Domaine Universitaire du Sart Tilman
    Liège, 4000, Belgium
    Recruiting
    • Pierre FRERES, Site 0012 · Contact+3243230000
  • Local Institution - 0129
    Salvador, Estado de Bahia 41253-190, Brazil
    Not yet recruiting
    • Site 0129 · Contact
  • Local Institution - 0121
    Porto Alegre, Rio Grande do Sul 90610-000, Brazil
    Not yet recruiting
    • Site 0121 · Contact
  • Local Institution - 0130
    Rio de Janeiro, 22451-100, Brazil
    Not yet recruiting
    • Site 0130 · Contact
  • Local Institution - 0124
    São Paulo, 01452-000, Brazil
    Not yet recruiting
    • Site 0124 · Contact
  • Local Institution - 0020
    Edmonton, Alberta T6G 1Z2, Canada
    Not yet recruiting
    • Site 0020 · Contact
  • The Ottawa Hospital Cancer Centre
    Ottawa, Ontario K1H 8L6, Canada
    Recruiting
    • Christina Canil, Site 0021 · Contact613737770070185
  • Princess Margaret Cancer Centre
    Toronto, Ontario M5G 2M9, Canada
    Recruiting
    • Srikala Sridhar, Site 0016 · Contact416-946-4501ext.2662
  • McGill University Health Centre
    Montreal, Quebec H4A 3J1, Canada
    Recruiting
    • Ramy Saleh, Site 0017 · Contact5149341934
  • Local Institution - 0050
    Beijing, Beijing Municipality 100034, China
    Not yet recruiting
    • Site 0050 · Contact
  • Local Institution - 0224
    Beijing, Beijing Municipality 100091, China
    Not yet recruiting
    • Site 0224 · Contact
  • Local Institution - 0048
    Fuzhou, Fujian 350001, China
    Not yet recruiting
    • Site 0048 · Contact
  • The First Affiliated Hospital Of Fujian Medical University
    Fuzhou, Fujian 350005, China
    Recruiting
    • Ning Xu, Site 0060 · Contact13235907575
  • Local Institution - 0056
    Xiamen, Fujian 361003, China
    Not yet recruiting
    • Site 0056 · Contact
  • Sun Yat-sen University Cancer Center
    Guangzhou, Guangdong 510060, China
    Recruiting
    • zhuowei liu, Site 0051 · Contact13610138571
  • The First Affiliated Hospital of Guangzhou Medical University
    Guangzhou, Guangdong 510120, China
    Recruiting
    • Yongda Liu, Site 0058 · Contact13719007083
  • Zhujiang Hospital
    Guangzhou, Guangdong 510280, China
    Recruiting
    • Abai Xu, Site 0226 · Contact
  • Local Institution - 0064
    Zhengzhou, Henan 450008, China
    Not yet recruiting
    • Site 0064 · Contact
  • Local Institution - 0059
    Changsha, Hunan 410013, China
    Not yet recruiting
    • Site 0059 · Contact
  • Nanjing Drum Tower Hospital The Affiliated Hospital of Nanjing University Medical School
    Nanjing, Jiangsu 210000, China
    Recruiting
    • Hongqian Guo, Site 0044 · Contact8613605171690
  • Local Institution - 0046
    Nanjing, Jiangsu 210009, China
    Not yet recruiting
    • Site 0046 · Contact
  • Local Institution - 0114
    Nantong, Jiangsu 226361, China
    Not yet recruiting
    • Site 0114 · Contact
  • The First Affiliated Hospital of Nanchang University
    Nanchang, Jiangxi 330006, China
    Recruiting
    • Bin Fu, Site 0206 · Contact13879103861
  • Shandong Cancer Hospital
    Jinan, Shandong 250117, China
    Recruiting
    • Jiasheng Bian, Site 0184 · Contact+8615954104097
  • The Affiliated Hospital of Qingdao University
    Qingdao, Shandong 266003, China
    Recruiting
    • Haitao Niu, Site 0156 · Contact18661803117
  • Yantai Yuhuangding Hospital
    Yantai, Shandong 264000, China
    Recruiting
    • Jian Chen, Site 0205 · Contact+86(0)53-5669-1999Ex
  • Local Institution - 0042
    Shanghai, Shanghai Municipality 200032, China
    Not yet recruiting
    • Site 0042 · Contact
  • Sichuan Cancer hospital
    Chengdu, Sichuan 610041, China
    Recruiting
    • Hong Liao, Site 0065 · Contact18908178867
  • West China Hospital, Sichuan University
    Chengdu, Sichuan 610066, China
    Recruiting
    • Jiyan Liu, Site 0225 · Contact8618980601768
  • Tianjin Medical University Cancer Institute & Hospital
    Tianjin, Tianjin Municipality 300060, China
    Recruiting
    • Xin Yao, Site 0052 · Contact13803000688
  • Local Institution - 0227
    Tianjin, Tianjin Municipality 300070, China
    Not yet recruiting
    • Site 0227 · Contact
  • Local Institution - 0157
    Hangzhou, Zhejiang 310022, China
    Not yet recruiting
    • Site 0157 · Contact
  • The First Affiliated Hospital of Wenzhou Medical University
    Wenzhou, Zhejiang 325000, China
    Recruiting
    • Wei Chen, Site 0053 · Contact+8613857771505
  • Tongji Hospital, Tongji Medical College of Huazhong University of Science and Technology
    Wuhan, 430030, China
    Recruiting
    • Xianglin Yuan, Site 0201 · Contact8613667241722
  • Local Institution - 0115
    Brno, Brno-město 656 53, Czechia
    Not yet recruiting
    • Site 0115 · Contact
  • Local Institution - 0146
    Hradec Králové, Hradec Králové 500 05, Czechia
    Not yet recruiting
    • Site 0146 · Contact
  • Local Institution - 0041
    Prague, Praha 5 150 06, Czechia
    Not yet recruiting
    • Site 0041 · Contact
  • Centre Antoine-Lacassagne
    Nice, Alpes-Maritimes 06189, France
    Recruiting
    • Delphine Borchiellini, Site 0009 · Contact+33492031000
  • CHU Strasbourg-Hautepierre
    Strasbourg, Alsace 67098, France
    Recruiting
    • Philippe Barthelemy, Site 0040 · Contact+33388116768
  • CHU de Bordeaux Hop St ANDRE
    Bordeaux, Aquitaine 33075, France
    Recruiting
    • Marine Gross-Goupil, Site 0004 · Contact+33556795679
  • Centre Leon Berard
    Lyon Cedex08, Auvergne-Rhône-Alpes 69373, France
    Recruiting
    • Aude Flechon, Site 0006 · Contact+33478782828
  • CHRU de Brest
    Brest, Finistère 29200, France
    Recruiting
    • Benjamin Auberger, Site 0258 · Contact+33 2 98 22 33 33
  • Hôpital Foch
    Suresnes, Hauts-de-Seine 92151, France
    Recruiting
    • Yann Alexandre VANO, Site 0223 · Contact+33146252000
  • Institut de Cancérologie de l'Ouest
    Saint-Herblain, Loire-Atlantique 44805, France
    Recruiting
    • Frederic Rolland, Site 0002 · Contact+33240679900
  • Local Institution - 0005
    Marseille, Provence-Alpes-Côte d'Azur Region 13273, France
    Withdrawn

    Not enrolling at this site — choose another above.

  • Centre Jean Perrin - Centre Régional de Lutte contre le Cancer d'Auvergne
    Clermont-Ferrand, Puy-de-Dôme 63011, France
    Recruiting
    • Hakim Mahammedi, Site 0003 · Contact+330473278080
  • Gustave Roussy
    Villejuif, Val-de-Marne 94800, France
    Recruiting
    • Yohann Loriot, Site 0001 · Contact+33142114211
  • Hôpital Européen Georges Pompidou
    Paris, 75015, France
    Recruiting
    • Constance THIBAULT, Site 0008 · Contact+33156092000
  • Groupe hospitalier Paris saint Joseph
    Paris, Île-de-France Region 75014, France
    Recruiting
    • Carole Helissey, Site 0007 · Contact+33144123333
  • NCT
    Heidelberg, Baden-Wurttemberg 69120, Germany
    Recruiting
    • Stefanie Zschaebitz, Site 0133 · Contact+49622156-3-9095

Showing the first 100 of 163 sites across 22 countries. Choose a country and city above to see the rest.

08

References and documents

Individual participant data

Plan to share: Yes — BMS will provide access to individual anonymized participant data upon request from qualified researchers, and subject to certain criteria. Additional information regarding Bristol Myer Squibb's data sharing policy and process can be found at https://www.bms.com/researchers-and-partners/clinical-trials-and-research.html

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: See Plan Description

Access criteria: See Plan Description

Data sharing details ↗ · www.bms.com

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Sep 2025 (actual). Primary completion is estimated for Jan 2029, 39 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 5, 2025
First posted
Aug 6, 2025
StartActual
Sep 30, 2025
Primary completionEst.
Jan 26, 2029
CompletionEst.
Nov 18, 2033
Last update
Jul 29, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 29, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07106762
Responsible party
Sponsor
First posted
Aug 6, 2025
Start date
Sep 30, 2025
Primary completion
Jan 26, 2029 (estimated)
Completion
Nov 18, 2033 (estimated)
Last update
Jul 29, 2026

Study contacts

BMS Clinical Trials Contact Center www.BMSClinicalTrials.com
Contact
Clinical.Trials@bms.com
855-907-3286
First line of the email MUST contain NCT # and Site #.
Contact
Bristol-Myers Squibb
study director · Bristol-Myers Squibb

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Izalontamab brengitecan

Start the discussion